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ABSTRACT
Podoplanin (PDPN) is a transmembrane glycoprotein that plays crucial roles in 
embryonic development, the immune response, and malignant progression. Here, we 
report that cells ectopically or endogenously expressing PDPN release extracellular 
vesicles (EVs) that contain PDPN mRNA and protein. PDPN incorporates into 
membrane shed microvesicles (MVs) and endosomal-derived exosomes (EXOs), where 
it was found to colocalize with the canonical EV marker CD63 by immunoelectron 
microscopy. We have previously found that expression of PDPN in MDCK cells induces 
an epithelial-mesenchymal transition (EMT). Proteomic profiling of MDCK-PDPN 
cells compared to control cells shows that PDPN-induced EMT is associated with 
upregulation of oncogenic proteins and diminished expression of tumor suppressors. 
Proteomic analysis of exosomes reveals that MDCK-PDPN EXOs were enriched in 
protein cargos involved in cell adhesion, cytoskeletal remodeling, signal transduction 
and, importantly, intracellular trafficking and EV biogenesis. Indeed, expression of 
PDPN in MDCK cells stimulated both EXO and MV production, while knockdown of 
endogenous PDPN in human HN5 squamous carcinoma cells reduced EXO production 
and inhibited tumorigenesis. EXOs released from MDCK-PDPN and control cells 
both stimulated in vitro angiogenesis, but only EXOs containing PDPN were shown 
to promote lymphatic vessel formation. This effect was mediated by PDPN on the 
surface of EXOs, as demonstrated by a neutralizing specific monoclonal antibody. 
These results contribute to our understanding of PDPN-induced EMT in association 
to tumor progression, and suggest an important role for PDPN in EV biogenesis and/
or release and for PDPN-EXOs in modulating lymphangiogenesis.
INTRODUCTION
Podoplanin (PDPN, also known as PA2.26 antigen, 
OTS-8, Aggrus, D2-40 and T1α) is a small mucin-like 
transmembrane glycoprotein expressed in different 
tissues that plays a crucial role in development of the 
heart, lungs and lymphatic vascular system [1]. PDPN is 
upregulated in a variety of cancers, including squamous 
cell carcinomas (SCCs) and glioblastomas, generally 
associated with poor prognosis [1, 2]. Elevated expression 
of PDPN is often found at the leading edge of invasive 
tumor nests [3–8], and has been identified as a marker of 
a cell subpopulation with stem-like characteristics in SCC 
and glioblastoma cell lines [9–11]. PDPN is also expressed 
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by inflammatory macrophages [12, 13] as well as cancer-
associated fibroblasts of various malignancies [14–19]. 
Previously, we have reported that PDPN induces an 
epithelial-mesenchymal transition (EMT) in transformed 
keratinocytes and Madin-Darby canine kidney (MDCK) 
cells associated with increased migration/invasion and 
lymph node metastasis formation [20–22]. In addition, 
other studies have shown that PDPN can stimulate 
collective tumor cell migration/invasion in the absence 
of EMT [4, 23]. Of note, antibodies and lectins targeting 
PDPN halt the growth and dissemination of PDPN-
expressing tumor cells [24–27].
PDPN is expressed at plasma membrane extensions, 
such as microvilli, filopodia and ruffles, where is linked 
to the actin cytoskeleton by binding ezrin and moesin, 
two members of the ERM (ezrin, radixin, moesin) protein 
family of cross-linkers between the plasma membrane and 
cytoskeleton [20, 22]. This interaction is crucial for PDPN-
mediated activation of RhoA GTPase and its downstream 
kinase ROCK to promote EMT [22]. Recently, we and 
others have found that PDPN is a component of ventral 
membrane protrusions called invadopodia that mediate 
degradation of the extracellular matrix (ECM) by tumor 
cells [28, 29]. The presence of PDPN in these structures is 
related to invadopodia stability and promotion of efficient 
matrix proteolysis [29]. In addition, PDPN interacts with 
the standard isoform of the hyaluronan receptor CD44s on 
the surface of carcinoma cells [30]. This interaction seems 
to be crucial for tethering tumor cells to hyaluronan-
rich ECMs [31] and for PDPN stimulation of directional 
migration [30]. PDPN also mediates cell adhesion 
through its interaction with the C-type lectin-like receptor 
2 (CLEC-2), which is present on platelets and immune 
cells [1]. PDPN-mediated platelet aggregation via CLEC-
2 interaction facilitates tumor cell growth and pulmonary 
metastasis [32, 33], whereas, in normal cells, this 
interaction is relevant for development of the lymphatic 
vasculature, lymphangiogenesis and the immune response 
[34–38]. In addition, PDPN is expressed in effector T cells 
and negatively regulates their survival in the target tissues, 
thus promoting tissue tolerance [39]. A fraction of PDPN 
is located in detergent-resistant membrane domains or 
lipid rafts [40, 41]. Importantly, the exclusion of PDPN 
from these platforms impairs promotion of EMT and cell 
migration [41].
Extracellular membrane vesicles (EVs) released 
by different types of cells are present in body fluids, 
such as blood, urine, semen and ascites, and serve as 
indicators in the diagnosis/prognosis of a variety of 
diseases [42–44]. EVs function as vehicles for intercellular 
communication, for transfer of proteins, lipids and RNA 
between cells (local or systemic), and have been involved 
in physiological and pathological processes, such as 
coagulation, inflammation, and tumor progression [42, 
45–47]. These circulating vesicles are a heterogeneous 
population of membrane structures that for simplification 
have been classified into two major categories: exosomes 
(EXOs) and microvesicles (MVs) or ectosomas [48]. 
EXOs are vesicles of 40-150 nm in diameter of endosomal 
origin that are released after the fusion of multivesicular 
bodies (MVBs) with the plasma membrane [49]. MVs, 
on the other hand, are a more heterogeneous population 
of vesicles, with sizes ranging from 100 nm to ≥ 1 μm. 
MVs are directly shed from the cell surface in a process 
that involves outward budding and fission of the plasma 
membrane [50]. Tumor cells themselves and cells in 
the tumor microenvironment secrete MVs and EXOs, 
and increasing evidence suggests that both type of 
vesicles contribute to tumor progression by stimulating 
angiogenesis, facilitating evasion of the immune 
surveillance and promoting cell migration/invasion and 
metastasis [43–47].
In this article, we demonstrate that PDPN is 
incorporated into the membrane of both EXOs and 
MVs. Comparison of the protein profiles of MDCK 
cells following PDPN expression reveals extensive 
reprogramming in whole cells and EXOs associated 
with EMT and tumor progression. Furthermore, this 
study provides experimental evidence supporting a role 
for PDPN in stimulating EV production and for PDPN-
expressing EXOs in modulating lymphangiogenesis.
RESULTS
PDPN is expressed in EVs released by different 
cell types
Ectopic expression of PDPN in MDCK 
cells (MDCK-PDPN) induces an EMT associated 
with downregulation of epithelial markers, such 
as E-cadherin and keratins, and induction of 
mesenchymal proteins; i.e. N-cadherin, allowing 
the conversion from an epithelial to a fibroblast-
like phenotype [22] (Supplementary Figure 
S1A, S1B). In experiments aimed to ascertain whether 
PDPN is shed from the cell surface, we identified 
full-length PDPN in the conditioned medium (CM) 
from MDCK-PDPN cells (Supplementary Figure 
S2A). Similarly, human HN5 squamous carcinoma 
cells, which express endogenous PDPN, released full-
length PDPN into the CM (Supplementary Figure 
S2B). Secreted PDPN was present in the pellet 
fraction following ultracentrifugation of the CM 
(Supplementary Figure S2A, S2B), revealing PDPN 
associated with EVs. All EV preparations that were 
isolated by standard procedures (crude EXO fractions; 
see Materials and methods) from different cell lines: 
HN5 cells and MDCK or human melanoma SK-
MEL-28 cells expressing PDPN tagged with enhanced 
green fluorescent protein (MDCK-PDPNeGFP, 
SK-MEL-28-PDPNeGFP), contained PDPN when 
analyzed by Western blotting (Figure 1). The isolated 
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crude EXO fractions were enriched for known 
exosomal proteins, such as CD63 and CD44 (Figure 
1A, 1B). Ezrin and activated (phosphorylated) ERM 
proteins known to interact with both PDPN and CD44 
[20, 22, 51] were also identified in EVs (Figure 1A). 
We have previously reported that PDPN undergoes a 
constitutive sequential proteolytic processing by an 
unknown metalloprotease followed by presenilin-1 
(PS1)/γ-secretase resulting in a ~33 kDa C-terminal 
membrane-bound fragment (PCTF33) and a ~29 
kDa cytosolic fragment containing the intracellular 
domain (PICD) [52]. Interestingly, both PCTF33 and 
PICD were identified together with the full-length 
protein (fl-PDPNeGFP) in the crude EXO fraction 
of MDCK-PDPNeGFP cells (Figure 1A), suggesting 
that PDPN cleavage may also occur in EVs, as it has 
been reported for CD44 and cadherin-17 [53, 54]. 
Indeed, the catalytic subunit of γ-secretase, PS1, is 
also incorporated into these vesicles (Figure 1B, 1C).
It has been reported that EVs contain select 
mRNAs that can be transferred to recipient cells and 
remain functional [55]. As the 3’ untranslated region 
of human PDPN mRNA contains a reported CTGCC 
core 25-nucleotide “zipcode” sequence (Supplementary 
Figure S3A) that can facilitate enrichment in EVs [56], 
we examined the presence of PDPN mRNA in EVs 
isolated from MDCK-PDPN and HN5 cells. Interestingly, 
a band of ~570 bp corresponding to PDPN mRNA was 
detected in the crude EXO fractions from these cells 
(Supplementary Figure S3B).
Localization of PDPN in MVBs and EXOs by 
confocal immunofluorescence and electron 
microscopy analysis
In order to explore whether cell-surface 
PDPN is endocytosed through a clathrin-dependent 
pathway, HN5 cells were labeled at 4°C with an 
anti-PDPN antibody (Ab). Labeled cells were then 
incubated at 37°C, and the presence of PDPN in 
early and late endosomes was identified by confocal 
immunofluorescence co-localization with early 
endosomal antigen 1 (EEA1) and CD63, respectively 
(Figure 2). Furthermore, double immunogold 
labeling and electron microscopy analysis detected 
the presence of PDPN (5-nm particles) and CD63 
(15-nm particles) in intraluminal vesicles of MVBs 
from thawed SK-MEL-28-PDPNeGFP cryosections 
(Figure 3). Most of PDPN labeling in SK-MEL-28-
PDPNeGFP cryosections was found at the plasma 
membrane, suggesting that only a minor fraction of 
cell-surface PDPN is internalized or, alternatively, 
that PDPN is actively recycled from endosomes to the 
plasma membrane. PDPN and CD63 were also found 
Figure 1: Western blot analysis of protein expression in whole cells and EVs isolated from different cell lines. EVs 
were isolated as crude EXOs by sequential ultracentrifugation as described in Materials and methods. A. MDCK cells expressing either 
PDPNeGFP or eGFP. B. HN5 cells expressing endogenous PDPN. C. SK-MEL-28 cells expressing either PDPNeGFP or eGFP. WCL, 
whole cell lysate.
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Figure 2: Confocal immunofluorescence reveals colocalization of PDPN with endosomal protein markers. HN5 cells 
were labeled at 4°C with anti-PDPN Ab and, after washing, incubated at 37°C for 40 min to analyze the presence of PDPN in early 
endosomes labeled with anti-EEA1 (upper panel) and 90 min to analyze the presence of PDPN in late endosomes labeled with anti-CD63 
(bottom panel). EEA1 and CD63 were detected using specific monoclonal Abs and AlexaFluor 546-conjugated goat anti-mouse IgG (red). 
PDPN was detected using AlexaFluor 488-conjugated goat anti-rabbit IgG (green). Scale bar, 10 μm.
Figure 3: Cryoelectron microscopy reveals MVB colocalization of PDPN and CD63. PDPN was detected in SK-MEL-28-
PDPNeGFP cells with a specific polyclonal Ab and protein A conjugated to 5-nm gold particles (small arrowheads), and CD63 with a 
specific monoclonal Ab and a goat anti-mouse conjugated to 15-nm gold particles (large arrowheads). Note the presence of PDPN in ILVs 
of MVBs, although most of PDPN labeling occurs at the plasma membrane (PM). Scale bar, 100 nm.
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to colocalize at the membrane of EVs released by these 
cells (crude EXO fraction) by electron microscopy 
analysis (Figure 4). Two different Abs recognizing 
PDPNeGFP, either directed against the ectodomain of 
PDPN (pdpn5 or pdpn15) or intracellular GFP (gfp5 or 
gfp15) were used. The EVs labeled for PDPN and CD63 
were of 72±19 nm (n=20), suggesting that vesicles are 
EXOs. EXOs derived from MDCK-PDPN and MDCK-
PDPNeGFP cells were also labeled for PDPN, while 
immunogold detection of CD63 was not observed due 
to the fact that the human-specific Ab did not recognize 
the canine protein epitope (Supplementary Figure S4).
PDPN is identified in EV subtypes
Since the EV fraction is a heterogeneous 
population mainly composed of endosomal derived 
EXOs and plasma membrane shed MVs [48], we asked 
whether PDPN is associated with only one or with both 
types of EVs. To this end, we isolated MVs and EXOs 
from MDCK-PDPN and MDCK-CMV control cells. 
EVs were isolated by differential centrifugation, and the 
crude EXO fraction obtained after ultracentrifugation, 
with purification using a density-based gradient 
fractionation, as outlined in Figure 5A. Western blot 
analysis of individual fractions revealed enrichment of 
EXOs (based on the exosomal marker Alix) and PDPN 
in fraction 8 (F8) with a buoyant density of 1.11 g/ml 
(Figure 5B). Dynamic light scattering analysis of EXO 
fractions from MDCK-CMV and MDCK-PDPN cells 
revealed a homogeneous distribution of ~ 85- and 90-
nm mean particles, respectively (Figure 5C). Expression 
of PDPN in MVs and EXOs released by MDCK-PDPN 
cells in the absence or presence of 10% serum (EV-
depleted) was compared by gel-based analysis of the 
same amount of total protein (10 μg) of EVs and cell 
lysates. Western blotting revealed that PDPN is present 
in MVs and EXOs, and that the presence of serum did 
not influence the incorporation of PDPN into either EV 
subtype (Figure 5D).
PDPN regulates EV production
It is widely accepted that production of EVs is 
upregulated during tumor progression [47]. Since PDPN 
expression in tumor cells is associated with increased 
malignancy [1, 2, 20–23], we explored whether PDPN 
modulates EV biogenesis. To address this aim, we 
Figure 4: PDPN immunoelectron microscopy of EVs isolated from SK-MEL-28-PDPNeGFP cells. PDPNeGFP was 
detected by two distinct rabbit polyclonal Abs directed either against the extracellular domain of PDPN (pdpn) or the intracellular tag 
GFP (gfp), and protein A conjugated to 5-nm gold particles (middle panels). The presence of CD63, an EXO marker, in EVs expressing 
PDPNeGFP was determined by double immunogold labeling using rabbit Abs against either PDPN or GFP and a specific monoclonal Ab 
to CD63. Signal was revealed by using an anti-rabbit Ab conjugated to 15-nm gold particles and an anti-mouse Ab conjugated to 5-nm gold 
particles (right panels). No signal was detected in control SK-MEL-28-eGFP cells. Scale bar, 100 nm.
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quantified protein content of MVs and crude EXOs 
isolated from the same number of MDCK, MDCK-
CMV and MDCK-PDPN cells (Figure 5A). Parental 
MDCK and control MDCK-CMV cells produced similar 
amounts of MVs and EXOs, while in MDCK-PDPN 
cells the amount of these vesicles was significantly 
enhanced ~1.5-1.7-fold (Figure 6A, 6B, upper panels). 
An increase in the content of Alix was also observed in 
MDCK-PDPN with respect to parental and control cells 
(Figure 6B, bottom panel). MDCK and derived cell lines 
produced ~10-fold more EXOs than MVs. Typically, 
the amount of MVs per 106 cells was 0.25 μg (MDCK, 
MDCK-CMV) to 0.4 μg (MDCK-PDPN), while crude 
EXO amounts were 2.8 μg (MDCK, MDCK-CMV) to 
4.2 μg (MDCK-PDPN).
The amount of EXOs produced by human HN5 
squamous carcinoma cells after PDPN knockdown by 
small hairpin RNA (shRNA) interference [30] was also 
quantified. Production of EXOs was reduced ~2-fold 
after downregulation of PDPN expression (>80%; see 
Figure 6C, left, upper panel), as measured by protein 
quantification (Figure 6C, right) and Western blot 
analysis of CD63 (Figure 6C, left, lower panel). Absolute 
values for EXOs were: 0.1-0.2 μg per 106 HN5-sh cells 
in comparison to 0.2-0.4 μg per 106 control cells. The 
amount of MVs produced by the HN5 cellular system 
was negligible. Moreover, the decreased production of 
EXOs by HN5-sh3 and HN5–sh4 cells with respect to 
control HN5-sc cells correlates with a drastic reduction 
of the tumorigenic potential of HN5 in nude mice. 
Whereas HN5-sc cells gave rise to tumors in all injection 
sites, the incidence of tumors induced by HN5-sh3 and 
HN5-sh4 cells decreased to 33% and 17%, respectively 
(Table 1). Taken together, these results indicate that 
PDPN stimulates EV biogenesis according to tumor 
progression.
Figure 5: Purification and characterization of EXOs released from MDCK-CMV and MDCK-PDPN cells. A. 
Experimental workflow for MV and EXO purification from MDCK-CMV and MDCK-PDPN cells. B. Western blot analysis of PDPN 
and Alix expression in fractions 6-9 from OptiPrep density-gradient performed with the crude EXO preparation from MDCK-PDPN cells. 
Note that significant enrichment of both Alix and PDPN were observed in fraction 8. C. Dynamic Light Scattering of EXOs from MDCK-
PDPN and control MDCK-CMV cells purified by OptiPrep density-gradient fractionation. D. Western blot analysis of PDPN expression in 
MDCK-PDPN cell lysate (WCL) and corresponding MV and EXO fractions derived from the conditioned medium in the presence/absence 
of 10% FBS (EV-depleted). * indicates a band of ~80 kDa that corresponds to a PDPN non-covalent homodimer identified in normal and 
tumor tissues [41].
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Cellular proteome analysis of MDCK-CMV and 
MDCK-PDPN
The protein profiles of MDCK-CMV and MDCK-
PDPN cell lysates were compared to reveal key insights into 
cellular changes as a consequence of PDPN expression. To 
investigate this, we cultured cells that were serum-starved 
for 24 h (to avoid serum-derived protein contamination 
in the CM). Serum-free conditions did not affect cell 
proliferation or viability (Supplementary Figure S5A, S5B). 
Using extensive and stringent informatics (protein FDR 1%, 
PEP 5%), the cellular proteomes retain a significant level of 
overlap with 835 proteins commonly detected for MDCK-
CMV and MDCK-PDPN cells while 97 and 84 proteins 
were uniquely detected in MDCK-PDPN and MDCK-CMV 
cells, respectively (Figure 7A, left). A list of cellular proteins 
highly enriched in MDCK-PDPN in comparison to control 
MDCK-CMV cells is shown in Supplementary Table S1. 
These proteins are involved in actin dynamics and focal 
adhesion (PLS3, EHD2, EPS8, FERMT2), ECM remodeling 
Figure 6: PDPN facilitates increased production and release of EV subtypes. A, B. Quantification of MVs (A) and EXOs (B) 
released by MDCK, MDCK-CMV and MDCK-PDPN cells. MVs and crude EXOs were isolated from the same number (2x106) of seeded 
cells, as indicated in the workflow presented in Figure 5A. After CM collection, cells were counted and used for normalization. EVs isolated 
from the CM were resuspended in the same volume (50 μl) of PBS, quantified and represented as a proportion per 106 cells. In panel B, a 
Western blot of Alix expression, as a protein marker of EXOs, is presented. The same volume (20 μl) of the crude EXO fractions was loaded 
onto each lane. C. Quantification of EXOs released by HN5 in response to PDPN knockdown. Two specific shRNAs (sh3, sh4) and shRNA 
control (sc) were used to deplete endogenous PDPN from HN5 cells. In the upper panel, a Western blot showing PDPN downregulation 
in HN5 cells in which GAPDH was used as a control of protein loading is presented. Aliquots of total cell lysates containing equivalent 
amount of proteins (30 μg) were loaded. In the lower panel, the Western blot shows diminished expression of CD63 as a measure of EXOs 
released by PDPN-knockdown cells. The same volume (20 μl) of crude EXO fractions were loaded. Results are expressed as the mean of 
three independent experiments α s.e.m. **p < 0.01 (A, B); *p < 0.05 (C).
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Figure 7: Proteomic profiling of MDCK cells and EXOs following PDPN overexpression. A. Two-way Venn diagram of 
proteins commonly and uniquely identified in MDCK-CMV and MDCK-PDPN cells and EXOs. B. Heatmap representing proteins for 
which an increase (red) or decrease (blue) in protein expression was observed in MDCK-PDPN EXOs compared to control MDCK-CMV 
EXOs. For EXOs, differentially expressed upregulated (upper) and downregulated (bottom) proteins are shown.
Table 1: Tumorigenicity of the HN5-derived cell lines in nude mice
CELL LINE NUMBER OF MICE 
WITH TUMORS
TUMORS / INJECTION 
SITES
LATENCIES  
(wks)a
HN5-sc 3/3 6/6 4-8
HN5-sh3 1/3 2/6 6-7
HN5-sh4 1/3 1/6 7
a The latency period is the time (weeks) needed for tumors to reach a size of 0.5 cm2
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(PLOD2, SERPINE1, CLIA2), intracellular trafficking 
and protein translocation (EHD2, KTN1, EPS8, SCFD1, 
PTPN1, SSR1), signal transduction (GNAS and CD109) and 
metabolism (HADHB, GLS, CYP51A1, PTPN1), and most 
of them have been found to promote tumorigenesis and/
or metastasis (see Supplementary Information). Similarly, 
proteins highly downregulated in MDCK-PDPN cells with 
respect to control are listed in Supplementary Table S2. 
They comprise cell adhesion, cytoskeletal components and 
ECM remodeling proteins (KRT7, KRT14, TES, JUP, 
EPCAM, CTNNB1, TGM2, SERPINB5), as well as proteins 
involved in the control of intracellular vesicle and protein 
transport (ANXA6, AP1B1, LLGL2, RAB8A, COPG2 and 
TOMM40), signal transduction (CTNNB1 and SPTBN1), 
metabolism (PLA2G7, IDH, TSTA3, ACY1, PFAS), protein 
synthesis (EIF4A2 and EIF4G1), RNA processing (DDX47, 
ESRP1) and regulators of the ubiquitin pathway (ISG15 
and TRIM28). Many of them seem to behave as tumor 
suppressors (see Supplementary Information).
Proteome analysis of EXOs released by MDCK-
CMV and MDCK-PDPN cells
The protein profiles of MDCK-CMV and MDCK-
PDPN purified EXOs were compared to reveal key insights 
into cargo-specific changes as a consequence of PDPN 
expression. The protein profiles of EXOs revealed 233 
proteins common for MDCK-PDPN and MDCK-CMV 
control cells, with EXOs from MDCK-PDPN cells enriched 
in specific proteins (Figure 7A, right). The top ten of these 
proteins are listed in the heat map of Figure 7B, right, 
upper panel, with a significant portion involved in vesicle 
trafficking and sorting (EHD2, ANXA8L1, MYO1C, 
FLOT1, RAP1B, RAB14). In fact, a large number of proteins 
enriched in MDCK-PDPN EXOs are implicated in the 
control of endocytosis and vesicle trafficking (Supplementary 
Table S3). These include members of the Rab, Ral an Rap 
subfamilies of small GTPases (RAB14, RAB1B, RAB13, 
RAB8B, RAB21, RAB35, RAB2A, RAB7A, RAB6A, 
RALA, RALB, RAP1B and RAP2B), annexins (ANXA8L1, 
ANXA4, ANXA7 and ANXA5), tetraspanins (CD151, CD82 
and TSPAN9), components of endosomal sorting complex 
required for transport (ESCRT) machinery (TSG101 and 
IST1), members of soluble N-ethylmaleimide-sensitive 
fusion attachment protein (SNAP) receptors (SNARE) 
machinery (STX7 and STXB3), and proteins involved in lipid 
raft formation (FLOT1, FLOT2, ZDHHC5), among others. 
Interestingly, the expression of most of these proteins are 
not significantly increased in whole cells, with the exception 
of EHD2, CD82 and ANXA5 that were also upregulated in 
MDCK-PDPN cells (Supplementary Table S3).
Other proteins enriched in MDCK-PDPN EXOs are 
involved in cell adhesion: integrins and members of the 
immunoglobulin family, cytoskeletal remodeling: tubulins, 
myosin and kinesin molecular motors, actin-binding 
proteins (Supplementary Table S4), and components of 
signal transduction pathways, particularly those involved in 
semaphorin and ephrin pathways (Supplementary Table S5).
A number of proteins were highly downregulated 
in MDCK-PDPN EXOs with respect to EXOs from 
control cells. These include mitochondrial ATP synthases 
(ATP5A1, ATP5B) and chaperonin (HSPD1), the 
component of ECM perlecan (HSPG2), the Rac GTPase 
activating protein RACGAP1, the kinesin-like protein 
KIF23/MKLP1 as well as cytoskeletal and cell adhesion 
proteins (EPCAM, CTNNB1, KRT7, KRT18) (Figure 7B, 
right, lower panel). Indeed, EXOs from MDCK-CMV and 
MDCK-PDPN cells showed the pattern of EMT changes seen 
in whole cells with downregulation of epithelial markers, 
such as components of cell-cell junctions: epthelial cell 
adhesion molecule (EPCAM), E-cadherin (CDH1), catenins 
(CTNNA1, CTNNB1), claudin 4 (CLDN4), desmoglein 3 
(DSG3), and cytoskeletal keratins (KRT7, KRT19, KRT18, 
KRT8) (Supplementary Table S6), and upregulation of 
mesenchymal proteins, such as N-cadherin (Figure 8A). 
The only exception was keratin 14 (KRT14) that was enriched 
by ~5 fold in MDCK-PDPN EXOs while downregulated 
by ~6 fold in whole cells (Supplementary Table S4). The 
significance of this observation is presently unknown.
EXO preparations from MDCK-CMV and MDCK-
PDPN cells contained actin along with canonical markers 
Alix and CD44, and were negative for the Golgi marker 
TGN46 (Figure 8A), reinforcing the use of highly purified 
EXO populations. The increase in annexin A7 and flotillin 
1 proteins in MDCK-PDPN EXOs found by proteomic 
analysis (Supplementary Table S3) was validated by 
Western blotting (Figure 8A). Likewise, the levels of 
these proteins decreased in EXOs released from PDPN-
downregulated HN5-sh3 cells compared to control HN5-sc 
EXOs (Figure 8B). The levels of Alix and CD9 remained 
unchanged in EXOs derived from MDCK and HN5 cell 
systems, respectively (Figure 8A, 8B).
Exosomes released from MDCK-PDPN cells 
stimulate lymphatic vessel formation
Next, we evaluated the effect of EXOs derived 
from MDCK-CMV and MDCK-PDPN cells on in vitro 
angiogenesis and lymphangiogenesis by measuring the 
ability of primary human umbilical vein endothelial cells 
(HUVEC) and human dermal lymphatic endothelial cells 
(HLECs) to organize into capillary-like structures on 
Matrigel. Both MDCK-CMV and MDCK-PDPN EXOs 
were able to stimulate the formation of HUVEC capillary-
like tubes at the same extent (Figure 9A, 9B). However, only 
EXOs from MDCK-PDPN cells were able to promote in 
vitro lymphangiogenesis (Figure 10A–10C). PDPN-EXOs 
significantly stimulated both the length of tubes (Figure 10A) 
and the number of closed capillary-like structures (Figure 
10B, 10C) formed by HLECs. The formation of lymphatic 
vessels was effectively inhibited by the anti-PDPN specific 
monoclonal antibody NZ1 in a dose-dependent manner, 
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but not by control IgG (Figure 10B, 10C), suggesting that 
modulation of in vitro lymphangiogenesis by PDPN-EXOs 
is mediated by PDPN.
DISCUSSION
We demonstrate that PDPN is secreted into the 
extracellular milieu as a component of different types of 
EVs: MVs and EXOs. Accordingly, PDPN should be added 
to the large list of lipid raft-associated proteins [40, 41] 
present in EVs [44]. EVs released by PDPN-expressing 
cells not only transport the protein but also the mRNA, 
reinforcing the possibility of PDPN transfer to target cells.
PDPN-induced EMT is associated with 
malignant progression
PDPN expression in MDCK cells promotes an EMT 
linked to increased cell migration and invasiveness [22]. 
Likewise, by comparing the proteome profiles of MDCK-
CMV and MDCK-PDPN cells, we show in this article that 
PDPN-induced EMT is associated with a reprogramming 
of proteins that favors tumor growth, invasiveness and 
metastasis. Thus, many proteins highly upregulated in 
MDCK-PDPN cells are pro-oncogenic and found to be 
overexpressed in different types of cancers, whereas most 
cellular proteins highly downregulated in MDCK-PDPN 
cells behave as tumor suppressors (Supplementary Tables 
S1 and S2 and Supplementary Information). These data 
provide an explanation for the acquisition of tumorigenic 
and metastatic capabilities observed in premalignant 
keratinocytes upon expression of PDPN [20, 21], and for 
the drastic reduction of tumorigenicity found in PDPN 
knocked-down HN5 carcinoma cells (Table 1).
PDPN modulates reprogramming of exosomal 
protein cargos
Our data reveal both quantitative and qualitative 
protein enrichment in EXOs containing PDPN with 
respect to control EXOs. The increase in protein content 
in MDCK-PDPN EXOs could be related to malignant 
progression, as EXOs from highly malignant cells 
contain higher amounts of proteins than EXOs from non-
Figure 8: Comparative Western blot analysis of protein expression in cells and EXOs from MDCK and HN5 cell 
systems. A. E-cadherin (E-CD) was downregulated while mesenchymal N-cadherin (N-CD) was upregulated in MDCK-PDPN cells 
and EXOs. Annexin A7 and flotillin 1 were upregulated in MDCK-PDPN EXOs. Both MDCK-PDPN and MDCK-CMV EXOs contained 
actin and CD44 and absence of the Golgi marker TGN46. B. Annexin A7 and flotillin 1 were downregulated in EXOs derived from PDPN 
knockdown HN5-sh3 cells while CD9 levels remained unchanged.
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malignant cells [57]. Interestingly, most proteins enriched 
in MDCK-PDPN EXOs were not overexpressed in whole 
MDCK-PDPN cells relative to MDCK-CMV control cells. 
These include cell-ECM and cell-cell adhesion receptors, 
cytoskeletal remodeling proteins, and components of 
signal transduction pathways, particularly those belonging 
to the semaphorin and ephrin pathways (Supplementary 
Tables S4 and S5). Semaphorins and ephrins besides their 
roles in axon guidance and development of the nervous 
system have been involved in angiogenesis, tumor 
invasion and metastasis, as well as in the recruitment and 
activation of tumor-associated immune cells [58–60].
Notably, MDCK-PDPN EXOs were enriched in 
proteins implicated in the regulation of intracellular vesicle 
trafficking (Supplementary Table S3). In fact, the most 
abundant protein present in MDCK-PDPN EXOs relative 
to control is EHD2, which besides regulating cell adhesion 
and motility is clearly implicated in the control of endocytic 
transport, although its precise function is still unknown 
[61]. Other proteins enriched in MDCK-PDPN EXOs are 
involved in EXO biogenesis and release; i.e., components of 
the ESCRT and SNARE machineries [44], or coordination 
of intracellular vesicle transport; i.e., tetraspanins, annexins 
and small Rab, Ral and Rap GTPases. Besides their role on 
membrane trafficking, tetraspanins participate in multitude 
of biological processes, including signal transduction, 
cell adhesion and motility and tumor cell invasion [62]. 
Interestingly, PDPN has been found to interact with 
Figure 9: MDCK-PDPN and MDCK-CMV-released EXOs stimulate in vitro angiogenesis. Representative micrographs 
A. and quantitative evaluation B. of the formation of closed capillary-like structures by HUVECs seeded on Matrigel-coated wells untreated 
(Control) or treated with MDCK-CMV and MDCK-PDPN crude EXOs (40 μg/ml). Data are expressed as the number of closed tubes per 
field. Bar, 150 μm. **p < 0.01. A representative experiment out of three is presented.
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the ubiquitous tetraspanin CD9 in tetraspanin-enriched 
membrane microdomains [63]. CD9 is present in both EXOs 
and MVs [64, 65], and whether this interaction is instrumental 
for PDPN segregation with these vesicles remains to be 
investigated. Among the RAB small GTPases enriched in 
MDCK-PDPN EXOs, RAB35 has been involved in exosome 
release mainly associated to early sorting endosomes [66]. 
Also, RAB14 and RAB21 are markers of early endosomes 
[67], whereas RAB7A located in late endosomes and 
lysosomes is involved in the secretion of Alix-containing 
EXOs [68]; another lysosomal protein enriched in MDCK-
PDPN EXOs is LAMP1. These observations suggest that 
MDCK-PDPN EXOs derived from different subpopulations 
of MVBs that fuse with the plasma membrane, as it has 
been generally observed for EXOs secreted by different 
cell types [44]. Cytoskeletal proteins that are involved in 
the mobilization, docking and fusion of MVBs with the cell 
surface, such as tubulins and associated molecular motors, 
kinesins and myosins [43] are also enriched in MDCK-PDPN 
EXOs (Supplementary Table S3).
The proteomic profile of EXOs derived from 
MDCK-PDPN cells has similarities with other EXO 
proteomes linked to EMT [69, 70]. In those cases, 
enrichment of proteins controlling vesicle-mediated 
trafficking was observed in EXOs derived from 
mesenchymal-like cells, which might result from 
changes on membrane fluidity and dynamics imposed 
by EMT [71]. In particular, comparison of the EXO 
protein profiles of MDCK-PDPN and MDCK-H-RAS 
cells reveals enrichment of 21 common proteins, 
including EHD2, ANXA4, ANXA5, CD151, TSPAN9, 
RAB21, RALA, ITGA6 and ITGAV among others. 
However, there are also important differences; i.e., 
increased expression of metalloproteases MMP1 and 
MMP14 is unique for EXOs from RAS-transformed 
MDCK cells [70], while EXOs from MDCK-PDPN but 
Figure 10: MDCK-PDPN-released EXOs stimulate in vitro lymphangiogenesis. A. Quantitative evaluation of the length of 
tubes per field formed by HLECs seeded on Matrigel-coated wells untreated (Control) or treated with MDCK-CMV and MDCK-PDPN 
crude EXOs (40 μg/ml) for 2 h and 4 h. A representative experiment out of two is presented. B, C. Representative micrographs (B) and 
quantitative evaluation of the number of closed capillary-like structures per field (C) formed by HLECs seeded on Matrigel-coated wells 
untreated (Control) or treated with MDCK-CMV and MDCK-PDPN crude EXOs (40 μg/ml) for 6 h. EXOs were preincubated with mAb 
NZ1 (0.5 μg/ml and 1 μg/ml) recognizing the extracellular domain of PDPN or control IgG (1 μg/ml), as indicated, for 1h at 4°C. Bar, 
100 μm. *p < 0.05. A representative experiment out of two is presented.
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not MDCK-H-RAS cells are enriched in components of 
the ephrin and semaphorin pathways, indicating a high 
degree of specificity in protein cargos incorporated into 
either EXO type despite EMT.
A novel function for PDPN as a modulator of EV 
biogenesis
The enhanced malignant characteristics of 
MDCK-PDPN with respect to control cells and the 
abundance of proteins implicated in vesicle biogenesis 
and secretion in MDCK-PDPN EXOs suggested a role 
for PDPN in promoting EV formation. A quantitative 
comparison of EVs isolated from the same number of 
control MDCK-CMV and MDCK-PDPN cells confirmed 
that this was the case. EV production (both EXOs and 
MVs) was significantly increased in MDCK-PDPN 
cells (Figure 6A, 6B). It can be argued, however, that 
this increase in EV formation was mostly due to EMT 
rather than to a direct effect of PDPN. Consequently, we 
performed a loss-of-function experiment by knockdown 
PDPN in HN5 SCC cells. PDPN silencing did not allow 
a major change in HN5 morphology, although these cells 
exhibited decreased spreading [30]. PDPN-downregulated 
cells exhibited reduced tumorigenicity and secreted ~2-
fold less EXOs than control and parental cells (Figure 6C). 
Taken together, these results suggest a regulatory role for 
PDPN on EV formation and/or secretion. Since PDPN is 
anchored to the actin cytoskeleton by ERM proteins and 
induces a major rearrangement of the actin cytoskeleton 
by activating RhoA and RhoC small GTPases [22, 29], 
its role on EV biogenesis may be exerted on processes 
dependent on actin-myosin dynamics, such as endocytosis, 
membrane fusion and exocytosis [43, 72]. In this respect, it 
is worth mentioning that a synergistic interaction between 
invadopodia and EXO secretion in cancer cells by which 
inhibition of invadopodia formation greatly reduces EXO 
release into the conditioned medium has been reported 
[73]. We have found that silencing of PDPN in HN5 cells 
impairs invadopodia stability and function [29], which 
may also contribute to reduced EXO production observed 
in PDPN-downregulated cells.
A role for PDPN-expressing EXOs as modulators 
of lymphatic vessel formation
In this report, we present preliminary evidence 
supporting a role for PDPN-EXOs in modulating 
lymphangiogenesis. Both PDPN-expressing and non-
expressing EXOs were able to stimulate blood vessel 
angiogenesis (Figure 9), a feature shared by EVs 
released from different types of tumor cells [42, 43, 47]. 
However, only PDPN-EXOs, but not control EXOs, 
were able to stimulate the formation of capillary-like 
structures of HLECs embedded in Matrigel (Figure 10). 
This stimulatory effect was abolished by targeting PDPN 
on the membrane of EXOs with a specific monoclonal 
antibody, indicating that is mediated by PDPN. PDPN 
is expressed in lymphatic endothelial cells [20, 74], 
and previous reports have found a crucial role for this 
glycoprotein in capillary morphogenesis and polarized 
migration of lymphatic endothelial cells via regulation 
of Rho family GTPase activities [75, 76]. Interestingly, 
soluble PDPN (a recombinant fusion protein of the 
extracellular domain of PDPN and Fc region of IgG) was 
shown to inhibit in vitro and in vivo lymphangiogenesis 
[77]. It remains to be established whether the effect of 
PDPN-EXOs involves the binding of PDPN to lymphatic 
chemokines, such as CCL21 [78], the interaction with a 
cell-surface receptor or the internalization by lymphatic 
endothelial cells. This feature might be relevant for 
malignant progression as tumor cells releasing PDPN-
EXOs may increase lymphangiogenesis around primary 
tumors and in the lymph nodes, thus contributing to the 
formation of the lymphvascular niche, and favor the 
spread of tumor cells to distant organs [79]. Experiments 
aimed to elucidate the effect of PDPN-EXOs on tumor 
lymphangiogenesis and metastasis are currently in 
progress.
MATERIALS AND METHODS
Cell culture, PDPN transfection, and RNA 
interference
MDCK cell transfectants stably expressing either 
untagged PDPN or PDPNeGFP have been previously 
described [3, 22]. SK-MEL-28-PDPNeGFP cells were 
obtained by infecting human melanoma SK-MEL-28 cells 
with a lentiviral vector containing PDPNeGFP [29]. Short-
hairpin RNAs (shRNAs) targeting human PDPN mRNA 
cloned into pLKO.1 vector and HN5 PDPNshRNA cell 
transfectants have been described elsewhere [30]. HN5 
and SK-MEL-28 cell lines identities were confirmed by 
short tandem repeat (STR) profiling and comparison with 
ATCC STR database.
Cells were routinely cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 
1% penicillin/streptomycin and 10% fetal bovine serum 
(FBS), at 37°C, in a humidified 5% CO2 atmosphere.
Cell proliferation and viability assays were 
performed by reduction of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) and trypan blue 
dye-exclusion, as previously described [80].
RT-PCR
Reverse transcription analysis for PDPN in EVs 
isolated from HN5 and MDCK-PDPN cells was performed 
as previously described [22, 30]. Specific primers were 
5’-GTGCTGGAATTCCCCGATGTGG-3’ and 5’-TCAG
GTACCCTGGGCGAGTACCTTCC-3’.
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Internalization and confocal 
immunofluorescence analysis
Internalization studies were carried out as 
described [81]. Briefly, cells were incubated in serum-
free medium at 37°C for 30 min to allow digestion 
of serum-derived ligands. After washing twice with 
cold Hank’s balanced salt solution supplemented 
with 20 mM Hepes, pH 7.2, and 2% BSA, cells were 
incubated with an anti-PDPN polyclonal Ab directed 
against the extracellular domain [3] at 4°C for 1h. After 
washing, cells labeled with anti-PDPN Ab on their 
surface were put at 37°C to allow endocytosis, and 
fixed (3.7% formaldehyde in PBS) and permeabilized 
(0.05% Triton X-100) at different times. Fluorescence 
detection of EEA1 and CD63 was performed with 
specific monoclonal Abs (1:200 dilution) from 
BD Bioscience and Immunostep, respectively, and 
AlexaFluor 546-conjugated goat anti-mouse IgG, as 
secondary Ab. Internalized PDPN was detected using 
AlexaFluor 488-conjugated goat anti-rabbit IgG (Life 
Technologies). Images were taken in a Zeiss LSM710 
confocal laser-scanning microscope (x63 oil objective).
EV isolation and purification
Isolation and purification of EVs was performed as 
previously described [70, 82]. Briefly, cells were grown to 
70% confluence, washed with serum-free DMEM medium, 
and cultured in this medium for 24 h. Conditioned medium 
(CM) was harvested and centrifuged twice (480 x g for 
5 min, 2000 x g for 10 min) to sediment floating cells and 
remove cell debris. CM was centrifuged at 10,000 x g for 
30 min to isolate shed MVs, and the resultant supernatant 
was further centrifuged at 100,000 x g for 1 h at 4°C to 
sediment the crude EXO fraction.
Crude EXOs were further purified using an 
OptiPrepTM density gradient as described [83]. The 
gradient was formed by adding 3 ml each of 40%, 20%, 
10% and 2.5 ml of 5% of iodixanol solution (Axis-
Shield PoC, Norway) to a 14 x 89 mm polyallomer tube 
(Beckman Coulter). Crude EXOs were resuspended in 
500 μl of PBS, loaded onto the top of the gradient, and 
centrifugation performed at 100.000 x g for 18 h at 4°C. 
Twelve individual 1 ml fractions were collected and each 
one was centrifuged at 100.000 x g for 1 h at 4°C. The 
supernatant were discarded and pellets washed with 1 ml 
PBS at 100.000 x g for 1 h at 4°C. After centrifugation, 
EXOs were resuspended in 50 μl of PBS. To determine 
the density of each fraction, a control OptiPrep™ 
gradient containing 1 ml of 0.25 M sucrose/10 mM Tris, 
pH 7.5 instead of sample was layered onto a second 
gradient and run in parallel. Fractions were collected 
as described, serially diluted 1:10,000 with water, and 
the concentration of iodixanol determined by measuring 
the absorbance at 244 nm using a molar extinction 
coefficient of 320 L g-1cm-1.
Electron microscopy and immunogold labeling
For electron microscopy analysis, the crude EXO 
fraction isolated from the cell lines were deposited on 
Formvar carbon-coated grids and immunolabeled with 
rabbit anti-PDPN Ab [3], at 1:250 dilution, or anti-GFP Ab 
(A-6455, Life Technologies; 1:500 dilution) and protein 
A conjugated to either 5-nm or 15-nm nanoparticles (Cell 
Microscopy Center, Utrecht University, The Netherlands). 
CD63 was labeled with mouse anti-CD63 monoclonal Ab 
(1:100, clone H5C6, Developmental Studies Hybridoma 
Bank, The University of Iowa) followed by goat anti-
mouse conjugated to 5-nm gold particles as described 
elsewhere [84]. For anti-GFP detection, EXOs were 
permeabilized with 0.1% saponin for 5 min before 
immunogold labeling. Samples were negatively stained 
with 2% uranyl acetate before visualization.
For immunogold labeling of cell cryosections, 
cells grown on 100-mm dishes were fixed in 2% 
paraformaldehyde and 0.2% glutaraldehyde in PHEM buffer 
(60 mM Pipes, 25 mM Hepes, 10 mM EGTA, 2 mM MgCl2) 
at pH 6.9 for 2 h, at room temperature, and kept in 1% 
paraformaldehyde in PHEM buffer at 4°C. Subsequently, 
cells were scraped and embedded in 10% (w/v) gelatin, 
cryoprotected for 16 h at 4°C with 2.3 M sucrose and frozen 
by immersion in liquid nitrogen. Samples were sectioned 
on an EM FCS cryo-ultramicrotome (Ultracut UCT, Leica) 
at -120°C. For immunogold labeling, thawed 90-nm-thick 
cryosections were incubated with rabbit anti-PDPN Ab 
(1:250) and mouse anti-CD63 monoclonal Ab followed by 
goat anti-mouse conjugated to 15-nm gold particles and 
goat anti-rabbit conjugated to 5-nm gold particles (Aurion, 
Wageningen, The Netherlands). Sections were stained with 
a mix of 1.8% methylcellulose and 0.4% uranyl acetate and 
visualized with a JEOL JEM 1010 (Tokyo, Japan) electron 
microscope at 80 kV. Images were recorded with a 4k x 4k 
CMOS F416 camera from TVIPS (Gauting, Germany).
Dynamic light scattering
Dynamic light scattering was performed with a 
Zetasizer nanoseries instrument (Malvern Instruments 
Ltd., UK), employing a 20 mW helium/neon laser, 633 
nm. All experiments were performed at 20 μg/ml in 
filtered PBS, in triplicate. Samples were studied at a 
constant temperature of 25 °C. Light scattering from the 
sample was detected by a photomultiplier tube placed at 
90° to the incident laser beam. EXO size data refers to the 
scattering intensity distribution (z-average) with standard 
deviation provided (Malvern software).
Protein quantification and immunoblotting
Cells were washed (ice cold PBS) and lysed on ice 
with SDS sample buffer (4% SDS, 20% glycerol, 0.01% 
bromophenol blue, 0.125 M Tris-HCl, pH 6.8. Lysates were 
subjected to ultracentrifugation for 30 min (336,000 x g, 
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TLA-100 rotor, Beckman Coulter), and soluble supernatants 
retained for downstream use, or frozen at -80°C. Protein 
quantification was performed as previously described [70].
For immunoblotting, membranes were probed with 
primary antibodies for 1 h in TTBS (50 mM Tris, 150 
mM NaCl, 0.05% Tween 20) followed by appropriate 
secondary Abs coupled to horseradish peroxidase. Primary 
Abs for phospho-ERM (1:1000), Alix (1:1000) and 
N-cadherin (1:1000) and TGN46 (1:1000) were from Cell 
Signaling; for ezrin (1:5000) and β-actin (1:10000) from 
Sigma Aldrich; for CD63 (1:1000) and GFP (1:5000) from 
Calbiochem; for PS1 (1:1000) from Abcam; for TSG101 
(1:1000) and flotillin 1 (1:1000) from BD Transduction 
Laboratories; for CD9 (1:1000) and annexin A7 (N-19, 
1:1000) from Santa Cruz Biotechnology; for GAPDH 
(1:1000) from Merck Millipore; for PDPN from Acris 
Antibodies (NZ1, 1:1000). For E-cadherin and CD44 
detection, the monoclonal Abs ECCD2 and HP2/9 
(a generous gift of Dr. F. Sánchez-Madrid), respectively, 
were used at 1:1000 dilution. Peroxidase activity was 
developed using an enhanced chemiluminiscence kit as 
indicated by the manufacturer (Pierce).
Proteomic analysis
Proteomic analyses were performed for cell lysates 
and purified EXOs (10 μg protein) as previously described 
[85] with modifications. Proteomic experiments were 
performed in biological duplicates and technical replicate. 
Samples were lysed in SDS sample buffer, electrophoresed 
by SDS-PAGE and visualized by Imperial™ Protein Stain 
(Thermo Fisher Scientific). Individual samples were 
excised (single gel bands and multi-band excision) and 
destained (50 mM ammonium bicarbonate/acetonitrile), 
reduced (10 mM DTT, Calbiochem, for 30 min), 
alkylated (50 mM iodoacetic acid, Fluka, for 30 min) and 
trypsinized (0.2 μg trypsin, Promega Sequencing Grade, 
for 16 h at 37°C), as described [85].
For all samples, peptides were desalted using 
reverse-phase C18 StageTips [86], and eluted in 85% 
acetonitrile (ACN) in 0.5% formic acid (FA). Peptides 
were lyophilised in a SpeedVac and acidified with buffer 
containing 0.1% FA, 2% ACN. A nanoflow UPLC 
instrument (Ultimate 3000 RSLCnano, Thermo Fisher 
Scientific) was coupled on-line to an Orbitrap Elite 
mass spectrometer (Thermo Fisher Scientific) with a 
nanoelectrospray ion source (Thermo Fisher Scientific). 
For cellular and EXOs samples, ~ 3 μg peptides were 
loaded (Acclaim PepMap100 C18 5μm 100Å, Thermo 
Fisher Scientific) and separated (Vydac MS C18-RP 
column, 25 cm, 75 μm inner diameter, 3 μm 300Å, Grace, 
Hesperia, CA) with a 120-min linear gradient from 
0-100% phase B (0.1% FA in 80% ACN) at a flow rate of 
250 nL/min. Details of the mass spectrometer operation 
are described previously [87].
Database searching and protein identification
Raw data were processed using Proteome 
Discoverer (v1.4.0.288, Thermo Fischer Scientific) 
enlisting a Human-Canine-Bovine-only (UniProt 
#195,909 entries) sequence databases (Apr-2015). 
Peptide lists were generated from a tryptic digestion 
with up to two missed cleavages, carbamidomethylation 
of cysteines as fixed modifications, and oxidation of 
methionines and protein N-terminal acetylation as 
variable modifications. Precursor mass tolerance was 10 
ppm, product ions were searched at 0.6 Da tolerances, 
min peptide length defined at 6, maximum peptide 
length 144, and max delta CN 0.05. Peptide spectral 
matches (PSM) were validated using Percolator based 
on q-values at a 1% false discovery rate (FDR) [88, 
89]. With Proteome Discoverer, peptide identifications 
were grouped into proteins according to the law of 
parsimony and filtered to 1% FDR [90]. Scaffold 
(Proteome Software Inc., Portland, OR, v 4.3.4) was 
employed to validate MS/MS-based peptide and protein 
identifications from database searching. Initial peptide 
identifications were accepted if they could be established 
at greater than 95% probability as specified by the 
Peptide Prophet algorithm [91]. Protein probabilities 
were assigned by the Protein Prophet algorithm [90]. 
Protein identifications were accepted, if they reached 
greater than 99% probability and contained at least 2 
identified unique peptides. These identification criteria 
typically established <0.01% FDR based on a decoy 
database search strategy at the protein level. Proteins that 
contained similar peptides and could not be differentiated 
based on MS/MS analysis alone were grouped to satisfy 
the principles of parsimony. Contaminants, and reverse 
identification were excluded from further data analysis.
Semiquantitative label-free spectral counting
Significant spectral count normalized (Nsc) and 
fold change ratios (Rsc) were determined as previously 
described [70]. The relative abundance of a protein 
within a sample was estimated using Nsc, where for 
each individual protein, significant peptide MS/MS 
spectra (i.e., ion score greater than identity score) were 
summated, and normalized by the total number of 
significant MS/MS spectra identified in the sample. To 
compare relative protein abundance between samples the 
ratio of normalized spectral counts (Rsc) was estimated. 
Total number of spectra was only counted for significant 
peptides identified (Ion score ≥ Homology score). When 
Rsc is less than 1, the negative inverse value was used. 
For each protein the Fisher’s exact test was applied 
to significant assigned spectra. The resulting p-values 
were corrected for multiple testing using the Benjamini-
Hochberg procedure.
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Tumorigenicity assays
All animal experiments were approved by the 
Animal Care and Use Committees of the CSIC and 
UAM. Mice were cared for following institutional 
guidelines for animal care and in accordance with the 
standards established in the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. For 
tumorigenicity assays, ~2.4 x 106 cells were intradermally 
injected into the two flanks of 8-10 weeks-old female 
Balb/c athymic nude mice (Harlan). The size of tumors 
was calculated from caliper measurements of two 
orthogonal diameters at different times. The latency of 
tumors was estimated as the time needed for tumors to 
reach a size of 0.5 cm2.
In vitro angiogenesis and lymphangiogenesis 
assays
In vitro formation of capillary-like structures was 
performed on growth factor-reduced Matrigel (Corning) 
with primary human umbilical vein endothelial cells 
(HUVECs) and human dermal lymphatic microvascular 
endothelial cells (HLECs) purchased from Lonza. 
HUVECs (104 cells per well) or HLECs (104 or 1.2 
x 104 cells per well) were seeded onto Matrigel-
coated wells in EBM2 (Endothelial Basic Medium) 
supplemented with EGM2 (Endothelial Cell Growth 
Medium BulletkitsTM, Lonza) with or without 40 μg/ml 
of crude EXOs from MDCK-CMV or MDCK–PDPN. 
The formation of capillary-like tubular structures was 
recorded microscopically at the indicated times. In 
order to test the involvement of PDPN in PDPN-EXO 
stimulation of lymphangiogenesis, both types of EXOs 
were preincubated for 1 h at 4°C with 0.5 and 1 μg/ml of 
rat mAb NZ1 directed against the extracellular domain of 
PDPN, or with 1 μg/ml rat IgG, as a control.
Statistical analysis
For quantification of MVs and EXOs isolated 
from cell lines, three independent experiments were 
carried out for each experimental condition. Data are 
presented as mean ± s.e.m. For in vitro angiogenesis 
and lymphangiogenesis assays, data are expressed as 
the mean ± s.e.m. of tube lengths (Image J software) 
in arbitrary units and/or the number of closed tube 
structures per field. Three different fields per well 
were counted in triplicate determinations. The figures 
shown are representative of two or three independent 
experiments, as indicated. Significance was determined 
using one-way analysis of variance followed by 
Bonferroni’s multiple comparison test. Data were 
considered as significant if p < 0.05 was reached. All 
statistical analyses were performed using GraphPad 
Prism 5.0 software.
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